ストックスクリーナーアプリを入手
34.02
1.37%
0.46
前日終値:
$33.56
開ける：
$33.77
24時間の取引高:
845.83K
Relative Volume:
0.76
時価総額：
$2.98B
収益：
$23.38M
当期純損益:
$-155.22M
株価収益率:
-15.53
EPS:
-2.19
ネットキャッシュフロー:
$-134.36M
1週間 パフォーマンス:
-5.16%
1か月 パフォーマンス:
+6.48%
6か月 パフォーマンス:
+52.69%
1年 パフォーマンス:
+31.96%
1日の値動き範囲:
$33.12
$34.25
1週間の範囲:
$33.12
$37.08
52週間の値動き範囲:
$13.45
$37.08
Ideaya Biosciences Inc Stock (IDYA) Company Profile
名前
Ideaya Biosciences Inc
セクター
電話
650-443-6209
住所
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
IDYA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
34.02 | 2.94B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-09-18 | 開始されました | Guggenheim | Buy |
| 2025-09-04 | 開始されました | Barclays | Overweight |
| 2025-09-04 | 開始されました | Citizens JMP | Mkt Outperform |
| 2025-07-22 | 開始されました | TD Cowen | Buy |
| 2025-07-10 | 再開されました | Goldman | Neutral |
| 2025-06-26 | 開始されました | Wells Fargo | Overweight |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-11-05 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-07-08 | 開始されました | Mizuho | Outperform |
| 2024-03-08 | 開始されました | BTIG Research | Buy |
| 2023-08-08 | 開始されました | SVB Securities | Outperform |
| 2023-05-24 | 開始されました | Goldman | Buy |
| 2023-04-24 | アップグレード | Stifel | Hold → Buy |
| 2023-03-23 | 開始されました | Berenberg | Buy |
| 2023-02-28 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-12-28 | 開始されました | CapitalOne | Overweight |
| 2022-10-27 | 開始されました | Citigroup | Buy |
| 2022-08-15 | ダウングレード | Stifel | Buy → Hold |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
| 2022-03-10 | アップグレード | Stifel | Hold → Buy |
| 2021-09-23 | 開始されました | Stifel | Hold |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-03-11 | 開始されました | Guggenheim | Buy |
| 2020-10-07 | 開始されました | Wedbush | Outperform |
| 2020-09-01 | 開始されました | Northland Capital | Outperform |
| 2020-07-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-06-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-06 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-13 | 開始されました | ROTH Capital | Buy |
| 2019-10-17 | 開始されました | Oppenheimer | Outperform |
| 2019-09-10 | 開始されました | Robert W. Baird | Outperform |
| 2019-06-17 | 開始されました | Citigroup | Buy |
| 2019-06-17 | 開始されました | JP Morgan | Neutral |
| 2019-06-17 | 開始されました | Jefferies | Buy |
すべてを表示
Ideaya Biosciences Inc (IDYA) 最新ニュース
Ideaya Biosciences to regain rights for two programs as GSK ends partnership - Investing.com India
IDEAYA financials not impacted by GSK termination, says Mizuho - MSN
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma - BioSpace
IDEAYA Hits Full Enrolment In Pivotal Trial Of Darovasertib For Metastatic Uveal Melanoma - RTTNews
IDEAYA Biosciences Completes Targeted Full Enrollment in Trial of Darovasertib With Pfizer's Crizotinib - marketscreener.com
IDEAYA completes enrollment for pivotal cancer drug trial By Investing.com - Investing.com Australia
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers - BioSpace
Stempoint Capital LP Purchases 98,886 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences submits IND for novel cancer drug IDE574 By Investing.com - Investing.com Australia
Ideaya Biosciences announces IND submission for IDE574 - marketscreener.com
Ideaya Biosciences Announces Ind Submission For Ide574 - TradingView
IDEAYA Biosciences (Nasdaq: IDYA) submits IND for IDE574, a KAT6/7 inhibitor in breast and lung cancer - Stock Titan
Hsbc Holdings PLC Has $804,000 Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Trading the Move, Not the Narrative: (IDYA) Edition - news.stocktradersdaily.com
Ideaya disclosed termination of GSK license agreement - MSN
GSK (GSK) Plans to End Agreement with Ideaya Biosciences - GuruFocus
IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 52-Week HighHere's Why - MarketBeat
GSK ends collaboration with IDEAYA for two candidates - MSN
Can IDEAYA Biosciences Stock Hold Up When Markets Turn? - Trefis
Schroder Investment Management Group Has $4.64 Million Holdings in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Why IDEAYA Biosciences Shares Are Under Pressure - TipRanks
GlaxoSmithKline to end collaboration with Ideaya Biosciences on two clinical programs - Investing.com Nigeria
IDEAYA Biosciences Shares Climb After FDA Clears Bispecific ADC Candidate - MSN
IDEAYA Biosciences Receives Termination Notice from GSK - TradingView
Ideaya Biosciences stock hits 52-week high at 36.57 USD By Investing.com - Investing.com Nigeria
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance - Business Wire India
Will IDEAYA Biosciences Inc. (30J) stock profit from automation wave2025 Short Interest & Advanced Swing Trade Entry Plans - Newser
IDE034, a Bispecific ADC Licensed by Biocytogen Pharmaceuticals Co., Ltd to IDEAYA Biosciences, Inc, Receives FDA IND Clearance - marketscreener.com
IDEAYA Biosciences (Nasdaq: IDYA) gets FDA IND for IDE034 Phase 1 solid tumor study - Stock Titan
How big funds are accumulating IDEAYA Biosciences Inc. (30J) stockJuly 2025 Fed Impact & AI Driven Price Forecasts - Newser
Ideaya Biosciences stock hits 52-week high at 36.57 USD - Investing.com
Is IDEAYA Biosciences Inc. (30J) stock a fit for income portfoliosGDP Growth & Weekly Top Gainers Trade List - Newser
Is IDEAYA Biosciences Inc. (30J) stock safe for risk averse investors2025 Performance Recap & AI Powered Buy and Sell Recommendations - Newser
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 52-Week HighTime to Buy? - MarketBeat
Transcript : IDEAYA Biosciences, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 09 - marketscreener.com
Can IDEAYA Biosciences Inc. stock beat market expectations this quarter2025 Top Gainers & High Yield Stock Recommendations - Newser
Can IDEAYA Biosciences Inc. stock beat analyst upgradesWeekly Profit Recap & Reliable Volume Spike Trade Alerts - Newser
Will IDEAYA Biosciences Inc. (30J) stock hit analyst forecastsTrade Ideas & Daily Profit Maximizing Tips - Newser
IDEAYA receives FDA approval to begin IDE034 clinical trial - Yahoo
Is IDEAYA Biosciences Inc. (30J) stock good for wealth creation2025 Big Picture & Technical Buy Zone Confirmation - Newser
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Citi Global Healthcare Conference - marketscreener.com
Ideaya Biosciences, Inc. Announces Ind Clearance for Ide034, A Potential First-In-Class Bispecific B7h3/Ptk7 Top1 Adc Targeting Multiple Solid Tumor Types - marketscreener.com
IDEAYA receives FDA clearance for bispecific cancer drug IDE034 By Investing.com - Investing.com Nigeria
Sector Update: Health Care Stocks Decline Pre-Bell Monday - marketscreener.com
IDEAYA Biosciences stock rises after FDA clearance for bispecific ADC By Investing.com - Investing.com Nigeria
IDEAYA Biosciences stock rises after FDA clearance for bispecific ADC - Investing.com
Ideaya’s IDE-034 gains IND clearance for solid tumors - BioWorld MedTech
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potenti - GuruFocus
IDEAYA Biosciences Gets FDA Clearance to Begin Phase 1 Trial of IDE034 in Early 2026 - marketscreener.com
Ideaya Biosciences announces clearance for IDE034 - marketscreener.com
Ideaya Biosciences Inc (IDYA) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):